



Atty. Dkt. No. 078883-0165

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Ole SIBBESEN et al.

Title: PROTEINS

Appl. No.: 10/626,583

Filing Date: 07/25/2003

Examiner: Unassigned

Art Unit: 1652

**RECEIVED**

AUG 19 2003

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/869,155, filed 10/01/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**

The relevance of the listed documents is described in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Aug 18, 2003

By Michele M. Simkin

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicants  
Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: August 12, 2003 (use as many sheets as necessary)		AUG 18 2003 JC34 PENT TRADEMARK OFFICE 1000/2900 <b>TECH CENTER 1600</b>	
Sheet	1	of	3
		Attorney Docket Number	
		078883-0165	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A19	McLAUCHLAN, W. Russell et al., "A novel class of protein from wheat which inhibits xylanases1", <i>Biochem. J.</i> , 338, ©1999 Biochemical Society, pp. 441-446, (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

AUG 18 2003

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

Substitute for form 1449B  
TRADEMARKINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: August 12, 2003

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

AUG 19 2003

TECH CENTER 1600/2900

Application Number	10/626,583
Filing Date	07/25/2003
First Named Inventor	Ole SIBBESEN
Group Art Unit	1652
Examiner Name	Unassigned

Attorney Docket Number 078883-0165

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A20	DEBYSER, W. et al., "Triticum aestivum Xylanase Inhibitor (TAXI), a New Class of Enzyme Inhibitor Affecting Breadmaking Performance", <i>Journal of Cereal Science</i> , 30, ©Academic Press, pp. 39-43, (1999)	
	A21	PAICE, Michael G. et al., "A xylanase gene from <i>Bacillus subtilis</i> : nucleotide sequence and comparison with <i>B. pumilus</i> gene", <i>Arch Microbiol.</i> , 144, © Springer-Verlag 1986, pp. 201-206, (1986)	
	A22	WOLF, Monika et al., "Genes encoding xylan and β-glucan hydrolysing enzymes in <i>Bacillus subtilis</i> : characterization, mapping and construction of strains deficient in lichenase, cellulase and xylanase", <i>Microbiology</i> , 141, pp. 281-290, (1995)	
	A23	YU, Ju-Hyun et al, "Nucleotide Sequence and Analysis of a Xylanase gene (xynS) from Alkali-tolerant <i>Bacillus</i> sp. YA-14 and Comparison with Other Xylanases", <i>Journal of Microbiology and Biotechnology</i> , Vol. 3, No. 3, pp. 139-145, (1993)	
	A24	YANG, Robert C. et al., "Nucleotide sequence of a <i>Bacillus circulans</i> xylanase gene", <i>Nucleic Acids Research</i> , Vol. 16, Number 14, ©IRL Press Limited, p. 7187, (1988)	
	A25	ROUAU, X. et al., "Evidence for the Presence of a Pentosanase Inhibitor in Wheat Flours", <i>Journal of Cereal Science</i> , 28, ©1998 Academic Press, pp. 63-70, (1998)	
	A26	DEBYSER, Winok et al., "Arabinoxylan Solubilization and Inhibition of the Barley Malt Xylanolytic System by Wheat During Mashing with Wheat Wholemeal Adjunct: Evidence for a New Class of Enzyme Inhibitors in Wheat", <i>J. Am Soc. Brew. Chem.</i> , 55(4), pp. 153-166, (1997)	
	A27	MAAT et al., "Xylanases and their application in bakery," <i>Xylans and Xylanases</i> (1992), J. Visser et al., ed., pp. 349-360, Elsevier Science Publishers B.V..	
	A28	FINCHER et al., "Cell Walls and Their Components in Cereal Grain Technology," <i>Advances in Cereal Technology</i> , (1986), Vol. VIII (Pomeranz, ed.), AACC, St. Paul, Minnesota, pp. 207-295.	
	A29	MEUSER et al., "Non-starch Polysaccharides," <i>Chemistry and Physics of Baking</i> , (1985), Royal Society of Chemistry, London, pp. 42-61.	
	A30	MCCLEARY, "Enzymatic modification of plant polysaccharides," <i>International Journal of Biological Macromolecules</i> , (1986) Vol. 8, pp. 349-354, Butterworth & Co..	
	A31	SLEAT et al., "Characterisation of the 5'-leader sequence of tobacco mosaic virus RNA as a general enhancer of translation in vitro," <i>Gene</i> (1987), Vol. 217, pp. 217-225, Elsevier Science Publishers B.V.	
	A32	DOWSON DAY et al., "Plant viral leaders influence expression of a reporter gene in tobacco," <i>Plant Mol. Biol.</i> (1993), Vol. 23, pp. 97-109, Kluwer Academic Publishers.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**O I P E**  
**AUG 18 2003**  
**TRADEMARKS & PATENTS**

Substitute for form 1449B <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: August 12, 2003 (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	3	of	3	Application Number	10/626,583
				Filing Date	07/25/2003
				First Named Inventor	Ole SIBBESEN et al.
				Group Art Unit	1652
				Examiner Name	Unassigned
				Attorney Docket Number	078883-0165

**RECEIVED**  
**AUG 19 2003**  
**TECH CENTER 1600/2900**

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A33	AN et al., "Transformation of Tobacco, Tomato, Potato and <i>Arabidopsis thaliana</i> Using a Binary Ti Vector System," <i>Plant Physiol.</i> (1986), Vol. 81, pp. 301-305.
	A34	BUTCHER et al., "The role of tissue culture in the study of crown-gall tumorigenesis," <i>Tissue Culture Methods for Plant Pathologists</i> (1980), pp. 203-208.
	A35	POTRYKUS, "Gene Transfer to Plants: Assessment of Published Approaches and Results," <i>Annu. Rev. Plant Physiol. Plant Mol. Biol.</i> (1991), Vol. 42, pp. 205-225.
	A36	WINTER ET AL., "Man-made antibodies," <i>Nature</i> (1991), Vol. 349, pp. 293-299.
	A37	ORLANDI ET AL., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci.</i> (1989), Vol. 86, pp. 3833-3837.
	A38	TAKEDA ET AL., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> (1985), Vol. 314, pp. 452-454.
	A39	NEUBERGER ET AL., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> (1984), Vol. 312, pp. 604-608.
	A40	MORRISON ET AL., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci.</i> (1984), Vol. 81, pp. 6851-6855.
	A41	COLE ET AL., "The EBV-Hybridoma Technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> (1985), Reisfeld et al., ed., pp. 77-96.
	A42	COTE ET AL., "Generation of human monoclonal antibodies reactive with cellular antigens," <i>Proc. Natl. Acad. Sci.</i> (1983), Vol. 80, pp. 2026-2030.
	A43	KOZBOR ET AL., "The production of monoclonal antibodies from human lymphocytes," <i>Immunol Today</i> (1983), Vol. 4, No. 3, pp. 72-79..
	A44	Koehler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> (1975), Vol. 256, pp. 495-497.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.